Perlmutter Cancer Center

The purpose of the study is to determine the recommended phase 2 dose for FT596 as monotherapy and in combination with rituximab or obinutuzumab for patients with Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia. We want to know the safety and tolerability of FT596 as monotherapy and in combination with rituximab or obinutuzumab. FT596 is expected to be uniform in composition, well tolerated, available off-the-shelf for potential use in multi-dose treatment cycles, and to have improved anti-tumor activity through a targeted approach. In this study, FT596 as monotherapy and in combination with rituximab or obinutuzumab are investigational, which means that they have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.